Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

This study has been withdrawn prior to enrollment.
(This study was withdrawn due to study agent availability.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Radiation Therapy Oncology Group Identifier:
First received: November 20, 2009
Last updated: June 21, 2013
Last verified: June 2013

RATIONALE: Monoclonal antibodies, such as conatumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine hydrochloride and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy may uses high energy x-rays to kill tumor cells. Giving conatumumab together with gemcitabine hydrochloride, capecitabine, and radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of conatumumab when given together with gemcitabine hydrochloride, capecitabine, and radiation therapy and to see how well they work in treating patients with locally advanced pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer
Biological: conatumumab
Drug: capecitabine
Drug: gemcitabine hydrochloride
Radiation: 3-dimensional conformal radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Induction Conatumumab and Gemcitabine, Followed by Conatumumab, Capecitabine and 3-D Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Radiation Therapy Oncology Group:

Primary Outcome Measures:
  • Dose-limiting toxicity (Phase I)
  • Overall survival (Phase II)

Secondary Outcome Measures:
  • Adverse events (Phase I and II)
  • Progression-free survival (Phase II)
  • Response rate (Phase II)

Enrollment: 0
Detailed Description:



  • To evaluate the maximum tolerated dose of conatumumab up to a target dose of 10 mg/kg given concurrently with capecitabine and radiotherapy following induction therapy comprising conatumumab and gemcitabine hydrochloride in patients with locally advanced pancreatic cancer. (Phase I)
  • To evaluate the overall survival of patients treated with this regimen. (Phase II)


  • To evaluate the safety profile in patients treated with this regimen. (Phase I and II)
  • To evaluate the progression-free survival of patients treated with this regimen. (Phase II)
  • To evaluate the primary tumor response rate in patients treated with this regimen. (Phase II)
  • To generate translational research hypotheses. (Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study of conatumumab, followed by a phase II study.

  • Induction therapy: Patients receive conatumumab IV over 30-60 minutes on days 1 and 15 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
  • Conatumumab and chemoradiotherapy: Beginning 14-42 days after the last course of induction therapy, patients undergo 3-dimensional radiotherapy once daily, 5 days a week, for 5½ weeks (28 treatments). Patients also receive conatumumab IV over 30-60 minutes on days 1, 15, and 29 and oral capecitabine twice daily, 5 days a week, for 5½ weeks.
  • Maintenance therapy: Beginning 28-56 days after completion of chemoradiotherapy, patients receive conatumumab IV over 30-60 minutes on days 1 and 15 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the pancreas

    • Locally advanced disease
    • With and without regional adenopathy
  • Unresectable disease based on institutional standardized criteria of unresectability OR medically inoperable
  • No distant metastatic disease, second malignancy, or peritoneal seeding


  • Zubrod performance status 0-1
  • Absolute granulocyte count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)
  • Serum creatinine ≤ 1.5 mg/dL
  • ALT or AST < 3 times upper limit of normal (ULN)
  • Total bilirubin < 3.0 mg/dL
  • Alkaline phosphatase < 3 times ULN
  • Amylase ≤ 2 times ULN
  • Lipase ≤ 2 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 3 months after the last study drug administration (for women) or for ≥ 6 months after the last study drug administration (for men)
  • Able to swallow oral medications
  • No other invasive malignancy within the past 2 years, except for nonmelanomatous skin cancer or carcinoma in situ of the breast, oral cavity, or cervix
  • No severe, active co-morbidity, including any of the following:

    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 30 days
    • Transmural myocardial infarction within the past 3 months
    • Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
    • Any other cardiac condition that, in the opinion of the treating physician, would make study treatment unreasonably hazardous for the patient
    • Acute bacterial or fungal infection requiring IV antibiotics
    • Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function
    • Any unresolved bowel or bile duct obstruction
    • Major resection of the stomach or small bowel that could affect the absorption of capecitabine
    • AIDS based upon current CDC definition

      • HIV testing is not required for study entry
  • No prior allergic reaction to capecitabine or gemcitabine hydrochloride


  • No prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields
  • No prior treatment with TRAIL-receptor agonists
  • No prior systemic chemotherapy for pancreatic cancer
  • More than 2 years since prior chemotherapy for malignancies other than pancreatic cancer
  • More than 28 days since prior major surgery (e.g., biliary or gastric bypass)

    • Insertion of a vascular access device, exploratory laparotomy, or laparoscopy are not considered major surgery
  • No concurrent intensity-modulated radiotherapy
  • No other concurrent chemotherapy
  • No other concurrent monoclonal antibody therapy
  • No concurrent sorivudine, brivudine A, or cimetidine
  • No concurrent participation in another clinical trial
  • Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is monitored
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01017822

Sponsors and Collaborators
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Christopher H. Crane, MD M.D. Anderson Cancer Center
  More Information

Responsible Party: Radiation Therapy Oncology Group Identifier: NCT01017822     History of Changes
Other Study ID Numbers: RTOG-0932
Study First Received: November 20, 2009
Last Updated: June 21, 2013

Keywords provided by Radiation Therapy Oncology Group:
adenocarcinoma of the pancreas
stage III pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 23, 2017